Novo Nordisk 2015 Profit Rises - Quick Facts

(RTTNews) - Novo Nordisk (NVO) reported that its 2015 net profit increased by 32% to DKK 34.9 billion. Earnings per share increased by 34% to DKK 13.52. Adjusted for the partial divestment of NNIT, net profit and earnings per share increased by 22% and 25% respectively. Operating profit increased by 43% in Danish kroner and by 21% in local currencies to DKK 49.4 billion.

Sales increased by 22% in Danish kroner and by 8% in local currencies to 107.9 billion.

For 2016, Novo Nordisk expects sales growth to be 5-9% measured in local currencies. Growth in operating profit is also expected to be 5-9% measured in local currencies, adjusted for the non-recurring impact of the partial divestment of NNIT and the income related to the out-licensing of assets for inflammatory disorders, both in 2015. Growth reported in DKK, for both items, is expected to be around 1 percentage point lower than the local currency levels.

Lars Rebien Sørensen, president and CEO, said: "In 2016 we will continue to focus on the global launch of Tresiba and we are encouraged by the recent SWITCH 2 data, which further demonstrate the ability of Tresiba to reduce the risk of hypoglycaemia in people with type 2 diabetes on basal insulin therapy."